



10/089932

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Continuation of PCT/PTO	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	MC13 Rec'd PCT/PTO 0-3 APR 2002
		Filing Date	
		First Named Inventor	Leyton
		Group Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	522-1783

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	TI
		Erlacher, "Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 Differentially Regulate Osteogenesis", Journal of Bone and Mineral Research, Vol. 13, No. 3, 1998, pp 383 - 392	
		Bradham, "In Vivo Cartilage Formation From Growth Factor Modulated Articular Chondrocytes", Clinical Orthopaedics and Related Research, No. 352, 1998, pp 239 - 249	
		Quarto, "Modulation of Commitment, Proliferation, and Differentiation of Chondrogenic Cells in Defined Culture Medium", Endocrinology, Vol. 138, No. 11, 1997, pp 4966 - 4976	
		Valcourt, "Different Effects of Bone Morphogenetic Proteins 2, 4, 12, and 13 on the Expression of Cartilage and Bone Markers in the MC615 Chondrocyte Cell Line", Experimental Cell Research, Vol. 251, No. 2, 1999, pp 264 - 274	
		Stewart, "Phenotypic Stability of Articular Chondrocytes In Vitro: The Effects of Culture Models, Bone Morphogenetic Protein 2, and Serum Supplementation", Journal of Bone and Mineral Research, Vol. 15, January, 2000, pp 166 - 174	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.